Skip to main content
. 2011 Jan;9(1):40–53. doi: 10.2174/157016211794582650

Table 5.

Percent Change from Baseline in Whole Body Composition by DEXA in STARTMRK

Raltegravir Efavirenz
Week N Baseline Mean (gm) Mean % Change(95% CI) N Baseline Mean (gm) Mean % Change(95% CI)
0 55 20408.54 56 17542.25
48 40 20095.34 18.10 (6.22, 29.98) 46 17776.56 19.99 (12.42, 27.57)
96 37 21487.02 19.63 (3.26, 36.01) 38 17566.83 21.04 (12.16, 29.92)

N = Number of patients in the treatment group.

Mean % change from baseline and are based on the measurements of the patients who were measured at baseline and the time point assessed.

The DEXA re-scan (for the baseline visit) values were taken as the baselines for 7 patients and clinically deemed acceptable, when the original baseline scan readings were not available.

Note: MK-0518 and Efavirenz were administered with tenofovir/emtricitabine.

HHS Vulnerability Disclosure